The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program® (TAP)

How can TAP benefit your company?

Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Expanding the Possible with Next-Generation Cell Therapies 

Leadership provided an overview of LLS Research’s impact on cell therapy and moderated a discussion panel with past and current TAP portfolio partners who are expanding the possible with next-generation cell therapy approaches for blood cancer patients. 

A recording of the presentation from Jan. 2022 is to the right.